OncoSil obtains FDA humanitarian exemption for bile duct cancer treatment

OncoSil Medical received FDA humanitarian device exemption approval to treat distal cholangiocarcinoma, a rare and deadly bile duct cancer, with a beta radiation therapy platform. The US launch will begin at up to five treatment centers under a post-approval study, aiming for Q2 FY27.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.